Form 4: Brainstorm Cell Therapeutics Director Stacy Lindborg Reports Acquisition of 20,000 Shares

Director Stacy Lindborg reports acquiring 20,000 shares of Brainstorm Cell Therapeutics through restricted stock units.

Summary

• On January 1, 2025, Stacy Lindborg, a director of Brainstorm Cell Therapeutics Inc., acquired 20,000 shares of common stock.
• These shares were obtained through restricted stock units (RSUs) awarded under the 2014 Stock Incentive Plan.
• 50% of the RSUs vested on the grant date, and the remaining 50% will vest six months later, contingent upon continued employment.
• The reported transaction reflects a post 1-for-15 reverse stock split adjustment.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally a good sign, but it's part of a compensation package and not an open market purchase.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the remaining RSUs is contingent upon the reporting person's continued employment with the issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's stock.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Brainstorm Cell Therapeutics, Director, Stacy Lindborg, Form 4, Stock Acquisition, RSUs, BCLI, Reverse Stock Split